🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children

Recruitingn/aAges 3 Months - 3 YearsAllCentre Hospitalier Intercommunal Creteil
NCT03825874 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The emergence of extended-spectrum beta-lactamase-producing Enterobacteriaceae (E-ESBL) is a major public health problem. It leads more frequent prescription of penems with the risk of emergence and spread of strains producing carbapenemases, which may be resistant to all known antibiotics. A policy of savings of penems is desirable. Among the alternatives to penems, amikacin is in the foreground. It remains active on the majority of E-ESBL strains. Some risk factors for E-ESBL emergence are known: recent antibiotic therapy (particularly quinolones and cephalosporins third generation), previous hospitalization or residence in a high endemic country. In pediatrics, E-ESBLs are primarily responsible for urinary tract infection. In France, E-ESBLs represent about 10% of the strains responsible for urinary tract infections. The Pathology Group Pediatric Infectious (GPIP) of the French Socie

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Infant and child (age ≥ 3 months and \<3 years) * Patient treated for febrile urinary tract infection as monotherapy with amikacin IV, ceftriaxone (IV or IM) or cefixime PO \* * Whose parents read and understood the newsletter and whose express consent was collected * Patient affiliated to a social security scheme (Social Security or Universal Medical Coverage) Exclusion Criteria: * Child treated with more than one antibiotic (eg treatment with dual therapy ceftriaxone / cefotaxime and aminoglycoside) * Antibiotherapy in progress or discontinued in the previous 7 days * Hospitalized child * Refusal of one of the parents
💊

What it tests

  • Amikacin
  • usual antibiotic treatment
📍

Where

20 sites
Cabinet du Dr Benali
Charenton-le-Pont, France
Cabinet du Dr Coicadan
Chennevières-sur-Marne, France
Cabinet du Dr Corrard
Combs-la-Ville, France
Cabinet du Dr Thollot
Essey-lès-Nancy, France
CHU Le Kremlin-Bicêtre
Le Kremlin-Bicêtre, France
157 Avenue du Général Leclerc
Maisons-Alfort, France
Centre Hospitalier de Meaux
Meaux, France
Cabinet du Dr Deberdt
Nogent-sur-Marne, France

…and 12 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy